Grifols sube en bolsa gracias a las perspectivas postivas
Radio Intereconomíaarrow_outwardGRF Hoy - Pronóstico 17/07: ¿Aguantará Breakout? (Gráficos)
DailyForexarrow_outward¿Por qué las acciones de Grifols suben un 20% en un mes?
XTB.comarrow_outwardWhat drives Grifols S.A. Depositary Receipt stock price - Phenomenal returns - Jammu Links News
Jammu Links Newsarrow_outwardWomen's EURO 2025 top scorer: Esther González - UEFA.com
UEFA.comarrow_outwardGrifols: Reassuring Evidence, Still On The Sidelines - Seeking Alpha
Seeking Alphaarrow_outwardGrifols to build new €160-million fractionation plant in Spain to double European production capacity - The Corner .eu
The Corner .euarrow_outwardGrifols to invest 160M euros in new manufacturing site - The Pharma Letter
The Pharma Letterarrow_outwardGrifols will invest €160 million in a new plant in Lliçà de Vall. - Diari ARA
Diari ARAarrow_outwardEquipment failure at Winnipeg clinic caused blood plasma donor's kidney injury, lawsuit alleges - CBC
CBCarrow_outwardGrifols shares rise 3.28% premarket after announcing a new manufacturing site in Spain to double plasma fractionation capacity. - AInvest
AInvestarrow_outwardShort Seller Gotham Beats Most of Grifols’ Defamation Claims - Bloomberg Law News
Bloomberg Law Newsarrow_outwardGrifols’s Family Blood Is Thicker Than Water - Bloomberg.com
Bloomberg.comarrow_outwardGrifols Case Shows It Paid Family-Linked Entity More for Plasma - Mint
Mintarrow_outwardOsborne Clarke advises Grifols on delisting offer and delisting from stock exchange of Biotest - Osborne Clarke
Osborne Clarkearrow_outwardAshurst advises Biotest on the public delisting offer by GRIFOLS and its delisting from the Frankfurt Stock Exchange - Ashurst
Ashurstarrow_outwardGrifols Completes Acquisition of Biotest Shares Following Delisting - TipRanks
TipRanksarrow_outwardXL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewswire
GlobeNewswirearrow_outwardUS court proceeds with Grifols defamation case against Gotham City, but narrows scope - Yahoo Finance
Yahoo Financearrow_outwardJudge Trims Most, But Not All, Of Grifols Suit Over Share Price - Law360
Law360arrow_outwardFDA clears Grifols’ application for dry eye disease treatment - Clinical Trials Arena
Clinical Trials Arenaarrow_outwardFDA clears Grifols' Investigational New Drug application for immunoglobulin drops for the treatment of DED - Ophthalmology Times
Ophthalmology Timesarrow_outwardIND Application Cleared for Phase II Trial of Grifols’ Dry Eye Disease Drops - PharmTech
PharmTecharrow_outwardGrifols says on course to meet 2025 outlook as net profit triples - yahoo.co
Yahoo.coarrow_outwardGrifols revenues rise 7.4% in Q1 after strong biopharma performance, shares jump - Investing.com UK
Investing.com UKarrow_outwardGrifols partners with IBL International - European Pharmaceutical Manufacturer
European Pharmaceutical Manufacturerarrow_outwardIBL partners with Grifols to develop biomarker panels for speciality diagnostics - Medical Device Network
Medical Device Networkarrow_outwardGrifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’ - SelectScience
SelectSciencearrow_outwardGrifols - drugdiscoverytrends.com
Drugdiscoverytrends.comarrow_outwardBrookfield revives €7bn takeover talks with Grifols as shares surge 11% - Private Equity Insights
Private Equity Insightsarrow_outwardSpanish pharma company Grifols' shares up on Brookfield talk - Reuters
Reutersarrow_outwardGrifols shares surge on reports of fresh Brookfield bid - Sharecast.com
Sharecast.comarrow_outwardGrifols Chair Symposium: Translating Science into the Clinic - Hospital Clínic Barcelona
Hospital Clínic Barcelonaarrow_outwardThe importance of time: Grifols seeks biomarkers for early diagnosis of disease - pharmaphorum
Pharmaphorumarrow_outwardGrifols IVIG Shows Promise for Post-Polio Syndrome - Contract Pharma
Contract Pharmaarrow_outwardGrifols collaborates with startup FcR Therapeutics to develop autoimmune therapies - PharmaTimes
PharmaTimesarrow_outwardSpain accused of 'scaring off and intimidating' short-sellers in Grifols case - IFR Asia
IFR Asiaarrow_outwardThe Michael J Fox Foundation for Parkinson’s Research awards grant to Grifols for pioneering study - Drug Target Review
Drug Target Reviewarrow_outwardGrifols garners $21M grant from Michael J. Fox Foundation to hunt for early Parkinson's disease biomarkers - Fierce Biotech
Fierce Biotecharrow_outwardMason Capital Pushes For Transparency At Troubled Grifols - Finimize
Finimizearrow_outwardMason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols - Business Wire
Business Wirearrow_outwardSpain: Grifols ends acquisition discussions with Brookfield - Investors in Healthcare
Investors in Healthcarearrow_outwardGrifols shares sink after Brookfield walks away from €6.45bn offer - Financial Times
Financial Timesarrow_outwardGrifols faces old issues as Brookfield walks away from takeover bid - FirstWord Pharma
FirstWord Pharmaarrow_outwardPlasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer - Fierce Pharma
Fierce Pharmaarrow_outwardCourt accepts complaint against Gotham for spreading 'biased and misleading' information about Grifols - Catalan News
Catalan Newsarrow_outward
Grifols close
- 2025-07-20 05:10 event
- 46 sourceslanguage
- 200+ ads_click
- 1 month ago schedule